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Abstract
Cannabinoid 1 receptors (CB1Rs) are expressed in peripheral tissues, including islets
of Langerhans, where their function(s) is under scrutiny. Using mouse b-cell lines,
human islets and CB1R-null (CB1R/) mice, we have now investigated the role of
CB1Rs in modulating b-cell function and glucose responsiveness. Synthetic CB1R
agonists diminished GLP-1-mediated cAMP accumulation and insulin secretion as
well as glucose-stimulated insulin secretion in mouse b-cell lines and human islets.
In addition, silencing CB1R in mouse b cells resulted in an increased expression of
pro-insulin, glucokinase (GCK) and glucose transporter 2 (GLUT2), but this increase
was lost in b cells lacking insulin receptor. Furthermore, CB1R/ mice had
increased pro-insulin, GCK and GLUT2 expression in b cells. Our results suggest that
CB1R signalling in pancreatic islets may be harnessed to improve b-cell glucose
responsiveness and preserve their function. Thus, our findings further support that
blocking peripheral CB1Rs would be beneficial to b-cell function in type 2 diabetes.
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1 | INTRODUCTION
Insulin-producing pancreatic b cells have to secrete insulin in a way
that maintains the blood glucose level in a narrow range at all times.
Glucose is the primary stimulus for insulin secretion, a process that
requires glucose sensing.1 Pancreatic b cells can sense and respond to
changing blood glucose concentrations with the help of glucose trans-
porter 2 (GLUT2) and glucokinase (GCK), which are the glucose-
sensing machinery.1 Blood glucose is transported into the b cells
through GLUT2, and GCK traps glucose in the cytoplasm by immediate
phosphorylation. Glucose metabolism in b cells generates ATP that
inhibits potassium efflux through KATP channels, resulting in b-cell
membrane depolarization and entry of extracellular Ca2+ through volt-
age-dependent Ca2+ channels, which then initiate insulin release. The
glucose dependency of insulin secretion is greatly enhanced by
increased adenylyl cyclase (AC) activity and in the fed state, enhanced
AC activity is generally controlled by the incretins, glucagon-like pep-
tide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP).
The binding of GLP-1 to its specific receptors (GLP-1Rs) on b cells
results in activation of AC, cAMP production and subsequent activa-
tion of PKA and the Epac family. This sequence of events leads to
enhanced glucose-dependent exocytosis of insulin from insulin-secre-
tory vesicles 2,3 and other downstream effects such as improved insu-
lin biosynthesis and increased pro-insulin, GLUT2 and GCK
expressions.4-6 Accordingly, altered glucose-sensing machinery of b
cells leads to defects in glucose-stimulated insulin secretion (GSIS).
Indeed, islets from diabetic Zucker rats have impaired GSIS due to
defective glucose sensing associated with a reduction in the expres-
sions of GLUT2 and GCK.7 Moreover, b-cell–specific knockout of
GLUT2 or GCK led to severe hyperglycaemia and infant death due to
impaired GSIS and, conversely, re-expression of GLUT2 in b cells res-
cued GLUT2-null mice from infant death and restored normal GSIS.8,9
b cells synthesize and secrete insulin as well as the known endoge-
nous cannabinoids (ECs).10-12 The ECs, 2-arachidonoylglycerol (2-AG)
and anandamide (AEA), are lipid transmitters that are not pre-stored in
granules, but are synthesized and released from cells only “on demand”
by Ca2+-dependent enzymes in the brain, fat, macrophages, and liver,
in addition to islets, following membrane depolarization.10-15 Thus,
both insulin secretion and EC synthesis are controlled by cell depolar-
ization and Ca2+ mobilization. The biological effects of ECs are medi-
ated by two G protein-coupled receptors (CB1R and CB2R), which,
when activated, inhibit AC activity and cAMP accumulation.15,16 CB1Rs
are expressed in neurons and peripheral tissues such as liver, adipose
tissue and skeletal muscle and contribute to food intake and peripheral
metabolic regulation including lipid and glucose homoeostasis and insu-
lin sensitivity.17-19 In fact, as ECs and CB1Rs are overactive in obesity
and type 2 diabetes (T2D), many scientists have been interested in
blockade of CB1R as a new therapeutic approach for the treatment of
obesity-related diseases. In addition, the majority of reports, including
our previous study,20-22 found that rodent and human b cells express
CB1Rs, whereas CB2Rs were not expressed in b cells11,20,23,24; how-
ever, there are also reports to the contrary.10-12,23,25
EC treatment of isolated mouse islets was reported to inhibit
GSIS and lower intracellular Ca2+ levels24; there are similar findings
from another group.25,26 However, the published literature is con-
flicting as regards the coupling of CB1Rs with Gai or Gas as well as
their effects on insulin secretion. It has been reported that in certain
circumstances, CB1R stimulation leads to Gas coupling, AC activa-
tion and increased GSIS.11,16,27-31 In addition, there are reports of
EC treatment of mouse islets leading to decrease in cAMP,16,28 while
increasing intracellular calcium and insulin secretion.16 Here, we eval-
uated human islets, several b-cell lines and CB1R-null (CB1R/)
mice in order to outline what the relevance of b-cell–derived ECs
might be to AC activity and insulin secretion. Moreover, we also
investigated the effect of CB1Rs on the expression of pro-insulin,
GLUT2 and GCK.
2 | MATERIALS AND METHODS
2.1 | Materials and reagents
The Rat/Mouse Insulin ELISA Kit was from Linco Research, and the
cAMP EIA kit was from Assay Designs. WIN55,212-2, CP 55,940,
arachidonyl-20-chloroethylamide (ACEA) and AM251 were obtained
from Cayman Chemical. Exendin-4 (Ex-4) was obtained from
Bachem. The human CB1R cDNA was amplified by RT-PCR from
human pancreatic RNA (Stratagene), with oligo-dT (18 bp) for the
reverse transcription. The CB1R cDNA was incorporated into a
mCerulean-N1 vector for CB1R-cerulean with the cerulean epitope.
2.2 | Cell culture and insulin secretion and cAMP
assays from cell lines
CHO-K1, CHO-GLP-1R (CHO-K1 cells stably transfected with GLP-
1R),32 CHO-GLP-1R-CB1R (CHO-GLP-1R cells stably transfected with
CB1R) 21 were maintained in DMEM/F-12 medium with 10% FBS.
bIRWT and bIRKO cells were established from control and b-cell–
specific insulin receptor (IR) knockout mice, respectively.20,22,33 Insu-
lin-secreting mouse b-cell lines (MIN6 and bTC6 cells) were main-
tained in DMEM medium with 10% FBS (Invitrogen). For insulin
secretion and cAMP assays, cells were plated in 12-well plates, 1 and
3 days before transfection, respectively. Cells were washed three
times in PBS and pre-incubated for 2 hours in Krebs buffer containing
4 mmol/L glucose, at 37°C. Subsequently, the cells were treated with
CB1R agonists (WIN 55,212-2, CP 55,940, ACEA or 2-AG) in the
absence and presence of CB1R antagonist AM215 (2.5 lmol/L) for
15 minutes prior to stimulation with glucose (4, 15, or 25 mmol/L),
forskolin (10 lmol/L) or Ex-4 (10 or 25 nmol/L) for 20 minutes. At the
end of the experiment, the buffer was collected, centrifuged to
remove cellular debris and saved for quantification of insulin. The cells
were lysed with 0.1 mol/L HCl and were centrifuged to remove cellu-
lar debris. The supernatant was collected for determination of cAMP
levels and protein concentrations. The cAMP levels were measured
using a cAMP EIA kit according to the manufacturer’s instructions. The
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data were normalized to insulin content or protein concentration and
estimated from three independent experiments, each performed in at
least triplicate. Transfections of the expression vectors and siRNA
(Santa Cruz) for CB1R were carried out 24 and 48 hours before adding
CB1R agonist using Lipofectamine 2000 and RNAiMAX (Invitrogen),
respectively. Scramble siRNA (Silencer Negative Control #1; Ambion)
or empty vector was transfected for negative control.
2.3 | Mice
CB1R/ mice and their wild-type littermates were developed and
backcrossed to a C57Bl/6J background as previously described.34
Two- to three-month-old male CB1R+/+ and CB1R/ mice were
used for this study. All animal care and experimental procedures fol-
lowed National Institutes of Health guidelines and were approved by
the National Institute on Aging Animal Care and Use Committee.
2.4 | Islet isolation and measurement of insulin
content and secretion in islets
Freshly isolated islets of Langerhans from human cadaveric donors
were obtained from the Islet Cell Resource Center. Mouse islets were
isolated from CB1R/ and age-matched CB1R+/+ mice using collage-
nase digestion as previously described.35 For insulin secretion assays,
we picked 10 size-matched islets per tube in Krebs buffer containing
4 mmol/L glucose followed by 30-minutes incubation at 37°C. We
pelleted the islets and replaced the buffer with Krebs solution contain-
ing the indicated glucose concentration. After 10-minutes incubation
at 37°C, we collected the supernatant for insulin measurement and
measured insulin content or protein concentration for normalization.
Insulin levels were determined from three independent experiments
performed in triplicate. Intra-islet insulin content was measured using
ice-cold acid-alcohol as we previously described.6
2.5 | Immunostaining
For frozen sections, mice were anaesthetized, and pancreata were
rapidly dissected, fixed in 4% paraformaldehyde, immersed in 20%
sucrose before freezing and then sectioned at a thickness of 7 lm.
After antigen unmasking, the slides were blocked with 5% BSA/PBS
and incubated at 4°C, with guinea pig anti-insulin (1:500; Millipore),
rabbit anti-GCK (1:100; Santa Cruz) and rabbit anti-GLUT2 (1:200;
Santa Cruz), followed by secondary antibodies (Invitrogen). Slides
were viewed under an LSM-710 confocal microscope (Carl Zeiss).
Using LSM Image Browser software (Carl Zeiss), multiple sections
from three mice per genotype, separated by at least 200 lm from
each section, were assessed for quantification of GCK and GLUT2.
2.6 | Quantitative real-time PCR analysis
Total RNAs were isolated from frozen mouse islets or bTC6 cells
using the TRIzol reagent (Thermo Fisher Scientific, Waltham, MA,
USA), according to the manufacturer’s protocol. All extractions were
followed by DNase I treatment (Invitrogen). After reverse transcrip-
tion (RT) using random hexamers and reverse transcriptase (Toyobo,
Osaka, Japan), the mRNA abundance was assessed using a CFX Con-
nectTM Real-Time PCR Detection System (Bio-Rad, Hercules, CA,
USA) and the SYBR green PCR master mix (Kapa Biosystems, Wilm-
ington, MA, USA). The 18S gene was used for normalization to quan-
tify the relative mRNA expression levels. Gene-specific primer
sequences were summarized in Table S1.
2.7 | Immunoblotting
Protein samples were extracted from cells using RIPA buffer
(50 mmol/L Tris-HCl at pH 7.4, 150 mmol/L NaCl, 1% NP-40, 0.1%
SDS, 1 mmol/L EDTA) containing protease and phosphatase inhibitor
cocktails (Calbiochem). They were then subjected to Tris-Glycine
PAGE (Invitrogen), immunoblotted with rabbit anti-CB1R (1:500;
Frontier Science), anti-insulin (1:1000; Santa Cruz), anti-GCK (1:500;
Abcam), anti-GLUT2 (1:1000; Santa Cruz) or mouse anti-b-actin
(1:10000; Abcam), and visualized by ECL (GE Health). Whole pancre-
ata were homogenized by a motor-driven pestle in ice-cold RIPA
buffer containing protease and phosphatase inhibitor cocktails.
Homogenates were solubilized by end-over-end mixing at 4°C for
60 minutes and subjected to centrifugation. Total protein was deter-
mined using Bradford assay (Bio-Rad).
2.8 | Statistical analysis
Quantitative data were presented as the mean  SEM. Differences
between mean values for variables within individual experiments
were compared statistically by Student’s t test. Comparisons were
performed using GraphPad Prism (GraphPad Software). A P value of
<.05 was considered statistically significant.
3 | RESULTS
3.1 | Activation of CB1Rs decreases cAMP
accumulation
Despite conflicting studies,36,37 the majority of reports on the
subject suggest that CB1Rs are present in pancreatic b
cells.10,11,15,23,24,38,39 Western blot analysis confirmed that CB1Rs
are expressed in mouse insulinoma cell lines (bTC6 and MIN6 cells)
but are lacking in CHO cell lines (CHO-K1 and CHO-GLP-1R) stably
transfected with vector and GLP-1R 32 (Figure 1A).
As activation of CB1R leads to reduced intracellular cAMP by
inhibiting AC via Gai class of heterotrimeric G proteins,15,16 we sur-
mised that ECs upon their discharge from b cells, which occurs after
membrane depolarization,10-12,15 would influence cAMP accumula-
tion and insulin secretion. To prove whether ECs inhibit AC activity
by activation of CB1Rs, we first transiently transfected CHO-GLP-
1R cells with vector (CHO-vector) or CB1R (CHO-CB1R) and acti-
vated AC in these cells using forskolin (Figure 1B). As expected, this
led to increased intracellular cAMP levels in CHO-vector cells,
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whereas ACEA, a highly selective CB1R agonist, did not impact the
effect of forskolin (Figure 1C). However, in CHO-CB1R cells, ACEA
significantly reduced forskolin-mediated intracellular cAMP genera-
tion (Figure 1C). Next, we investigated the effects of ACEA on
cAMP accumulation caused by Exendin-4 (Ex-4, a potent ligand of
the GLP-1R) in CHO-vector and CHO-CB1R cells. Under the condi-
tions of high GLP-1R expression, Ex-4 is a powerful stimulus to AC
activation and intracellular cAMP accumulation (Figure 1D). The inhi-
bitory effects of ACEA on Ex-4-stimulated cAMP accumulation were
not observed in CHO-vector cells, which is likely due to lack of
CB1Rs (Figure 1A). However, ACEA treatment in CHO-CB1R cells
transiently transfected with CB1R led to reduced cAMP accumula-
tion (Figure 1D). To further confirm the effects of CB1R agonism on
cAMP accumulation, we used another CB1R agonist CP 55 940 and
F IGURE 1 Effects of CB1R agonists on intracellular cAMP accumulation in CHO-GLP-1R cells. A, Western blot analysis showing CHO-K1
and CHO-GLP-1R (CHO-K1 cells stably transfected with rat GLP-1R) do not express CB1Rs, unlike insulin-secreting mouse b-cell lines (bTC6
and MIN6). Mouse brain was used as a positive control, and b-actin was used as a loading control. B, Overexpression of CB1R in CHO-K1
cells. Representative images of the mCerulean-vector- and mCerulean-CB1R-transfected CHO-K1 cells under a fluorescence microscope 24 h
after transfection. Western blot analysis of CB1R expression in CHO-K1 cells 24 h after mCerulean-CB1R transfection is shown on the right.
C, Effects of CB1R overexpression on forskolin-mediated cAMP accumulation. CHO-K1 cells stably expressing GLP-1R were transiently
transfected with empty vector (CHO-vector) or CB1R (CHO-CB1R) and pre-incubated with ACEA for 15 min prior to stimulation with
forskolin. D, Effects of CB1R overexpression on Ex-4-mediated cAMP accumulation in CHO-vector and CHO-CB1R cells. The cells were pre-
treated with ACEA for 15 min before the subsequent addition of Ex-4 for an additional 20 min. E, Forskolin-mediated cAMP accumulation in
CHO-GLP-1R cells stably transfected with empty vector (CHO-GLP-1R-vector) or CB1R (CHO-GLP-1R-CB1R). The cells were pre-incubated
with CP 55,940 for 15 min prior to stimulation with forskolin. F, Ex-4-mediated cAMP accumulation in CHO-GLP-1R-vector and CHO-GLP-
1R-CB1R cells. The cells were pre-treated with CP 55,940 for 15 min prior to stimulation with Ex-4. All values were normalized to protein
concentration. Data are shown as the mean  SEM from at least 3 independent experiments. *P < .05; **P < .01, n.s. = not significant
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alternate CHO-GLP-1R cells stably transfected with empty vector
(CHO-GLP-1R-vector) or CB1R (CHO-GLP-1R-CB1R).21 Consistently,
CP 55 940 abrogated both forskolin- and Ex-4-mediated cAMP
accumulation in CHO-GLP-1R-CB1R cells, but not in CHO-GLP-1R-
vector (Figure 1E, F), confirming the inhibitory action of ECs on AC
activity in a receptor-dependent manner.
3.2 | Activation of CB1Rs decreases insulin
secretion from pancreatic b cells
Having shown that ECs inhibit forskolin- and Ex-4-mediated AC acti-
vation and cAMP accumulation, we subsequently investigated their
effects in b cells. Ex-4-mediated cAMP accumulation in bTC6 cells
was significantly decreased by another synthetic CB1R agonist
WIN55,212-2 in a concentration-dependent manner (Figure 2A). Con-
sistently, WIN55,212-2 also abrogated Ex-4-mediated insulin secretion
from bTC6 cells (Figure 2B). Using human islets, we further confirmed
that the insulinotropic effects of Ex-4 were enhanced by blocking
CB1Rs with AM251, a CB1R antagonist (Figure 2C). These results
prove that ECs antagonize incretin-mediated effects in b cells.
We then examined the effect of CB1R on GSIS. As expected,
pharmacological activation of CB1R by WIN55,212-2 inhibited GSIS
from bTC6 cells in a concentration-dependent manner, and this
was counteracted by pre-incubation of the cells with AM251
(Figure 2D). Furthermore, ACEA and 2-AG inhibited GSIS from
human islets (Figure 2E). Overall, these results favour the conclusion
that ECs are inhibitory mediators of AC activity and insulin secre-
tion in b cells.
3.3 | Effects of CB1R ablation on gene expression
Next, we measured the abundance of intra-islet insulin and insulin
mRNA in b cells. Knockdown of CB1Rs by siRNA in bTC6 cells
enhanced insulin gene expression (Figure 3A). Freshly isolated islets
from CB1R/ mice had increased insulin content after acid-alcohol
extraction compared to those of age-matched wild-type (CB1R+/+) lit-
termates (Figure 3B), most likely as a direct result of up-regulation
of insulin gene expression (Figure 3C). Consistently, Western blot
analysis confirmed that pancreas of CB1R/ mice had significantly
increased level of pro-insulin compared to those of age-matched
CB1R+/+ mice (Figure 3D). In addition, we measured protein levels of
glucose-sensing apparatus involved in the early steps of GSIS and
glucose metabolism in b cells. Western blot analysis showed that
pancreas of CB1R/ mice had significantly increased level of GCK
and GLUT2 compared to those of CB1R+/+ mice (Figure 3D). Consis-
tently, levels of GCK (Figure 3E) and GLUT2 (Figure 3F) in fasting
F IGURE 2 Effects of CB1R agonists on insulin secretion. A and B, Relative intracellular cAMP (A) and insulin (B) concentrations secreted from
bTC6 cells treated with the synthetic CB1R agonist WIN55,212-2 before the subsequent addition of Ex-4. C, Effects of blocking CB1R on Ex-4-
mediated insulin secretion in human islets. Human islets were pre-treated with a CB1R inverse agonist AM251 before the subsequent addition of
Ex-4. D, Relative insulin concentrations secreted from bTC6 cells in response to glucose in the absence or presence of WIN55,212-2, AM251 or
both. E, Relative insulin concentrations secreted from human islets in response to glucose in the absence or presence of ACEA or 2-AG. All values
were normalized to protein concentration. Data are shown as the mean  SEM from three independent experiments. *P < .05; **P < .01
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state were significantly higher in b cells of CB1R/ mice compared
to those of CB1R+/+ mice.
3.4 | Inhibitory effects of CB1R on gene expression
depend on insulin receptor (IR) signalling
Our previous reports have shown direct evidence of physical and func-
tional interactions between CB1R and insulin receptors (IRs) in b cells, in
which activation of CB1R suppressed IR signalling pathway via IRS2-
AKT-FoxO1 by diminishing IR kinase activity.20,22 As IR signalling is a key
regulator that promotes the expression of insulin, GCK and GLUT2 in b
cells, we investigated whether CB1Rs regulate the expression of insulin,
GCK and GLUT2 in IR-dependent manner. For this, we employed b cells
established from wild-type (bIRWT) and b-cell–specific IR knockout
(bIRKO) mice 20,22,33 (Figure 4A), in which expression levels of CB1Rs are
similar (Figure 4B). Knockdown of CB1Rs by siRNA in bIRWT cells
enhanced the expression of insulin, GCK and GLUT2, whereas knockout
of IR abolished the ability of CB1R to regulate the expression of insulin,
GCK and GLUT2 (Figure 4C), suggesting that CB1R regulates the expres-
sion of insulin, GCK and GLUT2 by inhibiting IR signalling (Figure 4D).
F IGURE 3 Effects of blocking CB1R on intra-b-cell insulin content and glucokinase (GCK) and glucose transporter 2 (GLUT2) expressions.
A, CB1R and Insulin (Ins2) mRNA levels in bTC6 cells transfected with control (siCtrl) or CB1R (siCB1R) siRNA. B, Intra-islet insulin content
in islets isolated from CB1R+/+ and CB1R/ mice. Insulin was extracted from islets freshly isolated from CB1R+/+ and CB1R/ mice using
acid-alcohol (n = 3 separate isolates). Size-matched 10 islets per tube were analysed, and data were normalized to protein concentration. C,
Insulin (Ins1 and Ins2) mRNA levels in islets isolated from CB1R+/+ and CB1R/ mice (n = 4 separate isolates). Data were normalized to 18S
ribosomal RNA levels. D, Western blot analysis of preproinsulin, GCK and GLUT2 expressions in total lysates prepared from whole
pancreata of overnight-fasted CB1R+/+ and CB1R/ (n = 4 per genotype) mice. Signals on Western blots were quantified by densitometry
and are shown on the right. E and F, Immunofluorescent staining for GCK (E) and GLUT2 (F) in islets of overnight-fasted CB1R+/+ and
CB1R/ mice. Scale bar, 50 lm. Relative signal intensity for the indicated proteins in islets is shown on the right (n = 3 per genotype).
Quantification of GCK and GLUT2 intensities was shown on the right. Data are shown as the mean  SEM from three independent
experiments. *P < .05; **P < .01
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4 | DISCUSSION
As mentioned in the introduction, there are many reports of
CB1R expression on pancreatic b cells in mouse and
human 10,11,16,23,24,38,39 and we concur.20-23 Recent reports, including
our own,20 have also found that b cells contain the other components
of EC system including the necessary enzymes for their biosynthesis
and degradation, and have the capacity to generate ECs in response
to glucose stimulation even when islets are isolated from the
pancreas.10-12,20 As EC synthesis and insulin secretion are controlled
by membrane depolarization and Ca2+ mobilization,10-12,15,20,40 this
supports the notion that the metabolically derived stimuli to insulin
secretion also lead to EC generation and therefore should mean that
insulin secretion and EC generation are proportional to one another.
We have now found that ECs inhibit AC activity and that they inhibit
cAMP accumulation in b cells, which results in diminished insulin
secretion. Therefore, it seems reasonable to conclude that ECs limit
insulin secretion under physiological conditions.
Activated CB1Rs are coupled to Gai class of heterotrimeric G
proteins and can initiate signalling events including closure of Ca2+
channels, opening of K+ channels and inhibition of AC activity (with
its consequent decrease in cytosolic cAMP concentrations), resulting
in inhibition of neurotransmitter release.40 However, the effects of
CB1Rs on insulin release from b cells have not been firmly estab-
lished, and the available data are occasionally inconsistent. We found
that synthetic and endogenous ligands of CB1Rs reduced cAMP
accumulation and insulin secretion in b cells and the CB1R inverse
agonist prevented such effects. Moreover, Ex-4- and forskolin-
mediated intracellular accumulation of cAMP was reduced by CB1R
agonism in CB1R-transfected CHO-GLP-1R cells, but not in vector-
transfected cells that intrinsically lack CB1Rs, further eliminating the
possibility of any non-specific effects of CB1R ligands. This is consis-
tent with recent reports that show decreased intracellular cAMP
levels in isolated islets 16 and MIN6 cells 28 due to ACEA. Taken
together, we conclude that ECs influence insulin secretion in an
autocrine manner by acting as a brake on AC activity.
Islets from CB1R/ mice displayed increased intra-islet insulin,
in conjunction with insulin gene expression. Additionally, islets in
pancreata from overnight-fasted CB1R/ mice displayed increased
GCK and GLUT2 expression, compared to those from CB1R+/+ mice.
Moreover, knockout of IR abolished the ability of CB1R to regulate
the expression of insulin, GCK and GLUT2, indicating that CB1Rs
regulate their expression in IR signalling-dependent manner. All of
these factors combined are likely to be responsible for improved
insulin secretion by CB1R antagonism. The molecular basis of the
defective insulin secretion involves defects in the signal transduction
pathways, especially such as insulin receptor signalling pathway, that
are activated by increased glucose in pancreatic b-cells.41-43 b-cell
dysfunction due to defective insulin receptor signalling leads to alter-
ations in mechanisms that are responsible for the production and
secretion of insulin, and this alteration involves a reduction of
GLUT2 and GCK expression.44 bIRKO mice showed defective GSIS,
progressive glucose intolerance, as well as reduction in GCK and
GLUT2 gene expression in the islets of both non-diabetic and dia-
betic bIRKO mice.44 In addition, islets from diabetic Zucker rats
showed impaired GSIS associated with a reduction in the expres-
sions of GLUT2 and GCK,7 and mice with a b-cell–specific deletion
of glucose-sensing machinery revealed severe hyperglycaemia and
F IGURE 4 Effects of CB1R on gene expression depends on
insulin receptor (IR). A, Western blot analysis of IR b-subunit (IRb)
and GAPDH in bIRWT and bIRKO cells. B, Quantitative real-time
PCR analysis of CB1R expression in bIRWT and bIRKO cells. Data
were normalized to 18S ribosomal RNA levels. C, Quantitative real-
time PCR analysis of CB1R, insulin, GCK and GLUT2 expression in
bIRWT and bIRKO cells transfected with control (siCtrl) or CB1R
(siCB1R) siRNA. D, Schematic unifying the regulation of b-cell
function by ECs and CB1Rs. Data are shown as the mean  SEM
from three independent experiments. *P < .05; **P < .01
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infant death due to impaired GSIS. However, re-expression of
GLUT2 in b cells rescued the mice from infant death and restored
normal GSIS,8,9 showing that altered glucose-sensing machinery of b
cells leads to changes in GSIS. Taken together, it is possible to
hypothesize that blockade of CB1R increases insulin secretion and
improves insulin responsiveness, at least in part, by up-regulation of
insulin, GCK and GLUT2 gene expressions.
EC levels in circulating blood as well as the pancreas are
reported to be elevated in diabetes and obesity,10,12,45,46 but it is
highly unlikely that islet-derived ECs contribute to blood levels as
they degrade within the islets. However, it is possible that increased
EC tone (due to increased EC synthesis, receptor expression or
activity) affects the well-described incretin and glucose unrespon-
siveness of b cells in type 2 diabetes. Additionally, it was recently
found that AEA impaired insulin-stimulated AKT phosphorylation
and decreased glucose uptake in skeletal muscle cells,47 while CB1R
antagonism enhanced insulin responsiveness in skeletal muscle.48
Therefore, CB1R antagonists that have poor brain penetrance (to
lessen CNS side effects) might be useful as therapeutic agents in
type 2 diabetes where they would be expected to improve b-cell
function, improve glucose uptake into muscle and prevent or reduce
hepatic steatosis.
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